Quest Wins First Commercial Zika Test FDA Emergency-Use Approval

FDA approved the first emergency-use authorization for a commercially developed, molecular-based Zika virus diagnostics, developed by Quest's Focus Diagnostics subsidiary.

FDA issued an emergency-use authorization (EUA) April 28 for Quest Diagnostics Inc.'s Zika Virus RNA qualitative real-timeRT-PCR test, the first commercially developed molecular-based Zika test approved by the agency, according to the company.

The test, developed by Quest's Focus Diagnostics Inc. subsidiary, is a polymerase chain reaction diagnostic intended for the qualitative detection of RNA from the Zika virus in human serum...

More from Regulation

More from Policy & Regulation